Jefferies Maintains Buy on Amarin

Loading...
Loading...
Jefferies is out with its report today on Amarin
AMRN
, maintaining Buy. In a note to clients, Jefferies writes, "A competitor has raised questions raised over the validity of the statistical analyses used in the MARINE and ANCHOR studies, but for reasons we outline below, we remain positive on the statistical analysis plans and the eventual AMR101 commercial label. We continue to believe in a multi-billion market opportunity for AMR101. AMRN remains one of our top biotech picks." Jefferies maintains a $25 PT on AMRN. At the time of posting, shares of AMRN were trading pre-market at $18.86, up 1.84% from Thursday's close.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorAnalyst RatingsAmarinHealth CareJefferiesPharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...